Rizvi, Fatima http://orcid.org/0000-0002-9157-7635
Everton, Elissa http://orcid.org/0000-0003-3837-4924
Smith, Anna R. http://orcid.org/0000-0001-9552-6176
Liu, Hua
Osota, Elizabeth
Beattie, Mitchell
Tam, Ying
Pardi, Norbert
Weissman, Drew
Gouon-Evans, Valerie http://orcid.org/0000-0001-5424-6573
Funding for this research was provided by:
March of Dimes Foundation (6-FY14-530)
Article History
Received: 17 March 2020
Accepted: 24 December 2020
First Online: 27 January 2021
Change Date: 10 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-23322-6
Competing interests
: In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Drew Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. Relevant to this study, Drew Weissman and Norbert Pardi are also named on a patent describing the use of modified mRNA in lipid nanoparticles US patent US8,278,036 entitled “RNA containing modified nucleosides and methods of use thereof”. Mitchell Beattie and Ying Tam are employees of Acuitas Therapeutics, a company focused on the development of lipid nanoparticulate nucleic acid delivery systems for therapeutic applications. All other authors declare no competing interests.